The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Journal: Evidence-based Cardiology. 2013;(1): 40‑46

Read: 1437 times

Contact the author
Table of contents

To cite this article:

. Evidence-based Cardiology. 2013;(1):40‑46. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Close metadata

References:

  1. Wolf P.A., Abbott R.D., Kanne W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991;22:983-988.
  2. Benjamin E.J., Wolf P.A., D'Agostino R.B., et al. Impact of Atrial Fibrillation on the Risk of Death: the Framingham heart study. Circulation 1998;98:946-952.
  3. Conen D., Chae C.U., Glynn R.J., et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. J Am Med Assoc 2011;305:2080-2087.
  4. Wyse D.G., Waldo A.L., DiMarco J.P., et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833.
  5. Uretsky B., Young J.B., Shahidi F.E.,et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the Proved trial. J Am Coll Cardiol 1993;22:955-962.
  6. Gheorghiade M., Adams K.F., Colucci W.S. Digoxin in the management of cardiovascular disorders. Circulation 2004;109:2959-2964.
  7. Rathore S.S., Curtis J.P., Wang Y., et al. Association of serum digoxin concentration and outcomes in patients with heart failure. J Am Med Assoc 2003;289:871-878.
  8. Chan K.E., Lazarus J.M., Hakim R.M. Digoxin associates with mortality in ESRD. J Am Soc Nephrol 2010;21:1550-1559.
  9. Packer M., Gheorghiade M., Young J.B., et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 1993;329:1-7.
  10. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-533.
  11. Wyse D.G., Waldo A.L., DiMarco J.P., et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004;109:1509-1513.
  12. Hallberg P., Lindback J., Lindahl B., et al. Digoxin and mortality in atrial fibrillation: a prospective cohort study. Eur J Clin Pharmacol 2007;63:1201-1202.
  13. Elayi C.S., Whitbeck M.G., Charnigo R., et al. Is there an association between external cardioversions and long term mortality and morbidity-insights from the AFFIRM study. Circ Arrhythm Electrophysiol 2011;4:465-469.
  14. Domanski M., Fleg J., Bristow M., Knox S. The effect of gender on outcome in digitalis-treated heart failure patients. J Card Fail 2005;11:83-86.
  15. Butler J., Anand I.S., Kuskowski M.A., et al. Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT). Congest Heart Fail 2010;16:191-195.
  16. Withering W. An account of the foxglove and some of its medical uses, with prac- tical remarks on dropsy, and other diseases. In: Willins FA, Keys TE (eds). Classics of Cardiology. Vol. 1. New York, NY: Henry Schuman, Dover Publications; 1941:231-252.
  17. Gheorghiade M., Van Veldhuisen D.J., Colucci W.S. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation 2006;113:2556-2564.
  18. Roy D., Talajic M., Nattel S., et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667-2677.
  19. Poole-Wilson P.A., Swedberg K., Cleland J.G., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:9377.
  20. The ACTIVE I Investigators. Irbesartan in patients with atrial fibrillation. N Engl J Med 2011;364:928-938.
  21. Brodsky M.A., Greene H.L., The AFFIRM Investigators. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004;43:1201-1208.
  22. Van Gelder I.C., Groenveld H.F., Crijns H.J., et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010;362:1363-1373.
  23. Van Gelder I.C., Hagens V.E., Bosker H.A., et al. Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-1840.
  24. Zarowitz B.J., Gheorghiade M. Optimal heart rate control for patients with chronic atrial fibrillation: are pharmacologic choices truly changing? Am Heart J 1992;123:1401-1403.
  25. Eichhorn E.J., Gheorghiade M. Digoxin: current use and approach to toxicity. Prog Cardiovasc Dis 2002;44:251-266.
  26. Fauchier L., Grimard C., Pierre B., et al. Comparison of beta blocker and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure. Am J Cardiol 2009;103:248-254.
  27. Castagno D., Petrie M.C., Claggett B., McMurray J. Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. Eur Heart J 2012;33:1137-1141.
  28. Binder L., Fredrickson L. Poisonings in laboratory personnel and health care pro- fessionals. Am J Emerg Med 1991;9:11-15.
  29. Englund G., Hallberg P., Artursson P., et al. Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring. BMC Med 2004;2:8.
  30. Connolly S.J., Camm A.J., Halperin J.L., et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl j Med 2011;365: 2268-2276.
  31. Nattel S. Dronedarone in atrial fibrillation-Jekyll and Hyde? N Engl J Med 2011; 365:2321-2322.
  32. Ahmed A., Rich M.W., Love T.E., et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006;27:178-186.
  33. Slatton M.L., Irani W.N., Hall S.A. Does digoxin provide additional hemodynamic and autonomic benefit at higher doses in patients with mild to moderate heart failure and normal sinus rhythm? J Am Coll Cardiol 1997;29:1206-1213.
  34. Gheorghiade M., Ferguson D. Digoxin: a neurohormonal modulator in heart failure? Circulation 1991;84:2181-2186.
  35. Ferguson D.W., Berg W.J., Sanders J.S., et al. Sympathoin- hibitory responses to digitalis glycosides in heart failure patients: direct evidence from sympathetic neural recordings. Circulation 1989;80:65-77.
  36. Adams K.F. Jr, Gheorghiade M., Uretsky B.F., et al. Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol 2002;39:946-953.
  37. Ahmed A., Waagstein F., Pitt B., et al. Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the digitalis investigation group trial. Am J Cardiol 2009;103:82-87.
  38. Goldman R.H., Coltart J., Friedman J.P., et al. The inotropic effects of digoxin in hyperkalemia: relation to (Na+, K+)-ATPase inhibition in the intact animal. Circulation 1973;48:830-838.
  39. Pouleur A.C., Barkoudah E., Uno H., et al. Pathogenesis of sudden unex- pected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. Circulation 2010;122:597-602.
  40. Steinberg J.S., Sadaniantz A., Kron J., et al. Analysis of cause- specific mortality in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Circulation 2004;109:1973-1980.
  41. Rathmore S.S., Wang Y., Krumholz M. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002;347:1403-1411.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.